The Nominations Committee is responsible for preparing a slate of candidates for Board of Directors positions (one for each open Director position) for ratification by the membership, as well as identifying qualified candidates for appointment by the Board for the President-elect and Treasurers position.
Members of the Nominations Committee conduct interviews with potential President-elect and Treasurer candidates as well as Director candidates if deemed necessary.
Led by the Committee Chair, the Committee develops a report presenting the new members to the current board for approval at the May meeting.
Nominations Committee 2025-2026
Chair
Brian O’Rourke, PharmD
Ottawa, Canada
Past-President (2025 – 2026)
Eberechukwu Onukwugha, PhD
Professor, University of Maryland
Baltimore, Maryland, USA
Past-President (2024 – 2025)
Jens Gruger, PhD
Affiliate Professor
University of Washington
Freiburg, Germany
Past President (2023-2024)
Jan Hansen, PhD
Global Head of Health Economics and Value Assessment, Specialty Care
Sanofi
Scottsdale, Arizona, United States
At-Large Member
Rachael Fleurence, PhD, MSc
President and Founder
Apodeixis Strategies
Bethesda, MD, USA
At-Large Member
Stephanie Earnshaw, PhD
Principal
Access Strategy Consulting
Pittsboro, NC, USA
At-Large Member
Mohammed Al-Hanawi, PhD
Professor of Health Economics and Financing
King Abdulaziz University
Jeddah, Mekkah, Saudi Arabia
At-Large Member
Karen Lee, MA
Novartis Canada, Montreal, Canada
School of Epidemiology & Public Health, Faculty of Medicine
University of Ottawa, Ottawa, Canada
At-Large Member
Bodo Wiegand, MBA
Sr Advisor
QuantCo
Florianopolis, Brazil
At-Large Member
Viva Ma, PhD, MPH, MBA
Director, Portfolio Advocacy, APMA
Novartis
Singapore
Chief Executive Officer
Rob Abbott
Chief Executive Officer
ISPOR-The Professional Society for Health Economics and Outcomes Research
Lawrenceville, NJ